Alkermes Plc

ALKS · Moat type: REGULIERUNG

MoatScore

2/10

Fair Value

51 USD

Margin of Safety

-2.0 %

Rating

MEIDEN

GESCHÄFTSMODELL Alkermes develops and markets specialty pharmaceuticals primarily for psychiatric and neurological disorders, generating revenues from proprietary products (in particular Vivitrol and Aristada) as well as from technology licensing to third parties.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.